S-1MEF

As filed with the Securities and Exchange Commission on May 4, 2023.

Registration No. 333-

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

ACELYRIN, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   2834   82-2406735

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

 

 

ACELYRIN, INC.

4149 Liberty Canyon Road

Agoura Hills, California 91301

(805) 730-0360

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

Shao-Lee Lin, M.D., Ph.D.

Chief Executive Officer

4149 Liberty Canyon Road

Agoura Hills, California 91301

(805) 730-0360

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Chadwick Mills

Charles S. Kim

Anitha Anne

Cooley LLP

3 Embarcadero Center, 20th Floor

San Francisco, California 94111

(415) 693-2000

 

Mardi C. Dier

Chief Financial Officer and
Chief Business Officer
4149 Liberty Canyon Road
Agoura Hills, California 91301
(805) 730-0360

 

Alan F. Denenberg

Emily Roberts

Davis Polk & Wardwell LLP

1600 El Camino Real

Menlo Park, California 94025
(650) 752-2000

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box:  ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☒ (333-271244)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.

 

 

 


EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Securities Act”), for the sole purpose of increasing the aggregate number of shares of common stock offered by ACELYRIN, INC. (the “Registrant”) by 4,025,000 shares, 525,000 of which are subject to purchase upon exercise of the underwriters’ option to purchase additional shares of the Registrant’s common stock. The contents of the Registration Statement on Form S-1, as amended (File No. 333-271244), including all exhibits thereto (the “Earlier Registration Statement”), filed by the Registrant with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act, which was declared effective by the Commission on May 4, 2023, are incorporated by reference into this Registration Statement. The additional shares of common stock that are being registered for issuance and sale pursuant to this Registration Statement are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 of the Earlier Registration Statement.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

EXHIBIT INDEX

 

Exhibit
No.
   Exhibit Index
5.1    Opinion of Cooley LLP.
23.1    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of ACELYRIN, INC.
23.2    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of ValenzaBio, Inc.
23.3    Consent of Macias Gini & O’Connell LLP, independent auditor of ValenzaBio, Inc.
23.4    Consent of Cooley LLP (included in Exhibit 5.1).
24.1*    Power of Attorney.
107    Filing Fee Table.

 

*

Previously filed on the signature page to the Registrant’s Registration Statement on Form S-1 (File No. 333-271244), originally filed with the Securities and Exchange Commission on April 13, 2023 and incorporated by reference herein.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Agoura Hills, California on May 4, 2023.

 

ACELYRIN, INC.
By:  

/s/ Shao-Lee Lin

Name:   Shao-Lee Lin, M.D., Ph.D.
Title:   Chief Executive Officer

POWER OF ATTORNEY

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

  

Title

  

    Date    

/s/ Shao-Lee Lin

Shao-Lee Lin, M.D., Ph.D.

  

Founder, Chief Executive Officer and Director

(Principal Executive Officer)

   May 4, 2023

/s/ Mardi C. Dier

Mardi C. Dier

  

Chief Financial Officer and Chief Business Officer

(Principal Financial and Accounting Officer)

   May 4, 2023

*

Bruce C. Cozadd

   Director    May 4, 2023

*

Dan Becker, M.D., Ph.D.

   Director    May 4, 2023

*

Alan B. Colowick, M.D., M.P.H.

   Director    May 4, 2023

*

Henry O. Gosebruch

   Director    May 4, 2023

*

Patrick Machado, J.D.

   Director    May 4, 2023

*

Beth Seidenberg, M.D.

   Director    May 4, 2023

*

Dawn Svoronos

   Director    May 4, 2023

 

*By:  

/s/ Shao-Lee Lin

  Shao-Lee Lin, M.D., Ph.D.
  Attorney-in-fact
EX-5.1

LOGO

 

Chadwick Mills

T: (650) 843-5654

cmills@cooley.com

   Exhibit 5.1

May 4, 2023

ACELYRIN, INC.

4149 Liberty Canyon Road

Agoura Hills, California 91301

Ladies and Gentlemen:

We have acted as counsel to ACELYRIN, INC., a Delaware corporation (the “Company”), in connection with the filing by the Company of a Registration Statement on Form S-1 (the “Registration Statement”) with the Securities and Exchange Commission pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended, covering an underwritten public offering of up to 4,025,000 shares of the Company’s common stock, par value $0.00001 per share (“Shares”). The Registration Statement incorporates by reference the registration statement on Form S-1 (No. 333-271244), which was declared effective on May 4, 2023 (the “Prior Registration Statement”), including the prospectus that is part of the Prior Registration Statement (the “Prospectus”).

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the Prospectus, (b) the Company’s Amended and Restated Certificate of Incorporation, as amended, and Amended and Restated Bylaws, each as currently in effect, (c) the Company’s Amended and Restated Certificate of Incorporation, filed as Exhibit 3.2 to the Prior Registration Statement, and the Company’s Amended and Restated Bylaws, filed as Exhibit 3.4 to the Prior Registration Statement, each of which is to be in effect in connection with the closing of the offering contemplated by the Prior Registration Statement and (d) originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below.

We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of the certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than by the Company where due authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued against payment therefor as described in the Registration Statement and the Prospectus, will be validly issued, fully paid and non-assessable.

 

Cooley LLP 3 Embarcadero Center San Francisco, CA 94111

T:+1 415 693 2000 f:+1 415 693 2222 cooley.com


LOGO

May 4, 2023

Page Two

 

We consent to the reference to our firm under the caption “Legal Matters” in the Prospectus included in the Prior Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons who consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

Cooley LLP

 

By:  

/s/ Chadwick Mills

  Chadwick Mills

 

 

Cooley LLP 3 Embarcadero Center San Francisco, CA 94111

T:+1 415 693 2000 f:+1 415 693 2222 cooley.com

EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated March 24, 2023, except for the effects of the reverse stock split discussed in Note 15 to the financial statements, as to which the date is May 1, 2023, relating to the financial statements of ACELYRIN, INC., which appears in Amendment No. 2 to the Registration Statement on Form S-1 (No. 333-271244) of ACELYRIN, INC. We also consent to the reference to us under the heading “Experts” in Amendment No. 2 to the Registration Statement on Form S-1 (No. 333-271244) incorporated by reference in this Registration Statement.

/s/ PricewaterhouseCoopers LLP

San Diego, California

May 4, 2023

EX-23.2

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated March 24, 2023 relating to the financial statements of ValenzaBio, Inc., which appears in Amendment No. 2 to the Registration Statement on Form S-1 (No. 333-271244) of ACELYRIN, INC. We also consent to the reference to us under the heading “Experts” in Amendment No. 2 to the Registration Statement on Form S-1 (No. 333-271244) incorporated by reference in this Registration Statement.

/s/ PricewaterhouseCoopers LLP

San Diego, California

May 4, 2023

EX-23.3

Exhibit 23.3

Consent of Independent Auditor

We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of ACELYRIN, INC. of our report dated April 29, 2022, except for the presentation of the convertible preferred stock and common stock as described in Note 2 as to which the date is February 10, 2023, with respect to our audit of the financial statements of ValenzaBio, Inc. as of December 31, 2021, and for the year then ended.

We also consent to the reference of our firm under the caption “Experts” in the Registration Statement on Form S-1 (No. 333-271244) incorporated by reference in this Registration Statement.

/s/ Macias Gini & O’Connell LLP

San Jose, California

May 4, 2023

EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

Form S-1

(Form Type)

ACELYRIN, INC.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

 

                 
     Security
Type
  Security
Class
Title
  Fee
Calculation
or Carry
Forward
Rule
  Amount
Registered(1)
  Proposed
Maximum
Offering
Price Per
Unit(2)
  Maximum
Aggregate
Offering Price
  Fee Rate   Amount of
Registration
Fee
                 
Fees to Be Paid   Equity   Common stock, $0.00001 par value per share   457(a)  

4,025,000

  $18.00  

$72,450,000

  0.00011020  

$7,984

           
    Total Offering Amounts    

$72,450,000

   

$7,984

           
    Total Fees Previously Paid        
           
    Total Fee Offsets        
           
    Net Fee Due               $7,984(3)

 

(1)

Represents only the additional number of shares being registered and includes 525,000 shares of common stock issuable upon exercise of the underwriters’ option to purchase additional shares. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-271244), as amended (the “Earlier Registration Statement”).

(2)

Based on the public offering price.

(3)

The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered securities on the Earlier Registration Statement having a proposed maximum aggregate offering price of $548,550,000, which was declared effective by the Securities and Exchange Commission on May 4, 2023. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $72,450,000 is hereby registered, which includes shares issuable upon the exercise of the underwriters’ option to purchase additional shares.